Pharmaceutical Care of Listeria Meningitis in a Child with Normal Immunity

doi:10.19803/j.1672-8629.2020.09.16

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the treatment of children with Listeria monocytogenes meningitis. Methods Clinical pharmacists participated in the medication of a child with Listeria monocytogenes meningitis. Pharmaceutical care involved the selection of antibiotics, drug dosage, adverse drug reactions, therapeutic effect and course of treatment. Results The patient got better and was discharged from the hospital Eventually. Conclusion Participation of clinical pharmacists in clinical treatment can provide individualized treatment for patients, which can help improve clinical treatment and promote rational drug use.Keywords: children; Listeria monocytogenes meningitis; pharmaceutical care

CLC Number:

R994.11

YANG Xue, FANG Lingzhi, WEI Lina, JI Hongyan, DONG Lei. Pharmaceutical Care of Listeria Meningitis in a Child with Normal Immunity[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 622-624.

References

[1] 《抗菌药物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则[M].北京:人民卫生出版社,2015:60-61.
[2] 何礼贤,肖永红,陆权,等.国家抗微生物治疗指南[M].2版.北京:人民卫生出版社,2017: 7.
[3] 桑福德.热病:桑福德抗微生物治疗指南[M].44版.范洪伟译.北京:中国协和医科大学出版社,2016:9.
[4] 迈克沙兰. 儿童抗感染性疾病蓝皮书[M].3版.申昆玲等译.北京:科学文献技术出版社,2015:610.
[5] 杨建伟. 单核细胞增生性李斯特菌最新研究进展[J].齐鲁医学杂志,2013,10(5):465-467.
[6] 孙照琨,吴璇,陈蕊,等.李斯特菌病既往中国文献报告病例分析[J].中国微生态学杂志,2016,28(11):1323-1325.
[7] Cohen SH,Gerding DN,Johnson S,et al.Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol,2010,31(5) : 431-455.
[8] 约翰惠普金斯.ABX指南[M].2版.北京:科学技术文献出版社,2012:654.
[9] van de Beek D, Cabellos C, Dzupova O, et al. diagnosis and treatment of acute bacterial meningitis[J]. Clinical Microbiology and Infection, 2016,22(3):37-62.
[10] Krawczyk Balska A,Markiewicz Z.The intrinsic cephalosporin resistome of Listeria monocytogenes in the context of stress response, gene regulation, pathogenesis and therapeutics[J]. Journal of Applied Microbiology,2015,120:251-265.
[11] 杨建伟. 单核细胞增生性李斯特菌最新研究进展[J].齐鲁医学杂志,2013,28(5):465.
[12] 王文娟,刘晶,赵金辉.感染产单核李斯特菌的孕妇临床特点及药敏分析[J].现代检验医学,2010,25(2): 131-133.
[13] 刘桂华,黄鑫,张炜煜.食品中金黄色葡萄球菌和单核细胞增生李斯特菌抗药性检测及结果分析[J]. 中国卫生工程学,2018, 17(4): 497-498.
[14] Pasquale P, Ferhat A, Tiziana A.Epidemiology and treatment of the commonest form of listeriosis:meningitis and bacteraemia[J].Le Infezioni in Medicina,2017,25(3):210-216.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.